GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (NAS:VRNA) » Definitions » Cash-to-Debt

Verona Pharma (Verona Pharma) Cash-to-Debt : 5.30 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Verona Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Verona Pharma's cash to debt ratio for the quarter that ended in Dec. 2023 was 5.30.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Verona Pharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Verona Pharma's Cash-to-Debt or its related term are showing as below:

VRNA' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.3   Med: 5016.16   Max: No Debt
Current: 5.3

During the past 13 years, Verona Pharma's highest Cash to Debt Ratio was No Debt. The lowest was 5.30. And the median was 5016.16.

VRNA's Cash-to-Debt is ranked worse than
53.12% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs VRNA: 5.30

Verona Pharma Cash-to-Debt Historical Data

The historical data trend for Verona Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Verona Pharma Cash-to-Debt Chart

Verona Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.31 31.61 25.55 21.40 5.30

Verona Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.40 14.20 13.25 12.68 5.30

Competitive Comparison of Verona Pharma's Cash-to-Debt

For the Biotechnology subindustry, Verona Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verona Pharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verona Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Verona Pharma's Cash-to-Debt falls into.



Verona Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Verona Pharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Verona Pharma's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verona Pharma  (NAS:VRNA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Verona Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Verona Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Verona Pharma (Verona Pharma) Business Description

Traded in Other Exchanges
Address
3 More London Riverside, London, GBR, SE1 2RE
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. The company is engaged in pharmaceutical development.
Executives
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
David R Ebsworth director C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Kathleen A. Rickard officer: Chief Medical Officer C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Christina Ackermann director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Claire Poll officer: General Counsel C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Mark W Hahn officer: Chief Financial Officer 6340 QUADRANGLE DRIVE, SUITE 100, CHAPEL HILL NC 27517
David Zaccardelli director, officer: President and CEO 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Rishi Gupta director, 10 percent owner C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Access Industries Holdings Llc 10 percent owner C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019
Ai Biotechnology Llc 10 percent owner C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Access Industries Management, Llc 10 percent owner 730 FIFTH AVENUE, NEW YORK NY 10019
Len Blavatnik 10 percent owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
James Aloysius Brady director C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Lisa Deschamps director C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE